Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - rivastigmine gppl is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. amitriptyline gppl 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. amitriptyline gppl 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - voriconazole, quantity: 40 mg - suspension, powder for - excipient ingredients: citric acid monohydrate; titanium dioxide; sodium citrate dihydrate; xanthan gum; sodium benzoate; colloidal anhydrous silica; sucrose; flavour - voriconazole pfs gppl is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - anagrelide hydrochloride, quantity: 0.61 mg (equivalent: anagrelide, qty 0.5 mg) - capsule, hard - excipient ingredients: lactose monohydrate; microcrystalline cellulose; lactose; gelatin; povidone; magnesium stearate; titanium dioxide; crospovidone - anagrelide gppl capsules are indicated for the treatment of essential thrombocythaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; sodium stearylfumarate; povidone; lactose; crospovidone; purified talc - modafinil gppl is indicated:,- to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy;,- to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate;,- as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red - moxonidine gppl is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red - moxonidine gppl is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - orlistat, quantity: 120 mg - capsule, hard - excipient ingredients: gelatin; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; sodium lauryl sulfate; indigo carmine aluminium lake - orlistat gppl is indicated for the treatment of obese patients with a body mass index (bmi) ? 30, and overweight patients with a bmi ? 27 in the presence of other risk factors, in conjunction with a mildly hypocaloric diet

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.